A Phase 2 interventional study of Padsevonil in Drug-Resistant Epilepsy and Focal-Onset Seizures, sponsored by UCB Biopharma SRL. Terminated at 156 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-29.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.
Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 5th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2018, is one of 9 in phase 2, and was the 17th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18–70
NeuroOne Medical Technologies Corporation · Sites in United States
Duke University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 3–25
Mayo Clinic · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 40 (60%) stop at 75 or younger; 26 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 17 · Phase 3 7 · Phase 4 2
First in 2001; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Median enrollment 27 across the 67 interventional studies, 100 across the 7 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 4 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
13 of the studies in Drug Resistant Epilepsy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT06425029Dartmouth-Hitchcock Medical CenterSelf-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application | 2026-12 |
| NCT06138808Duke University5-SENSE Score Validation Study | 2027-01 |
| NCT05273970University of ArizonaElectrochemical and Electrophysiological Study | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 78 studies in Drug Resistant Epilepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the long-term safety and tolerability of Padsevonil administered at individualized doses as adjunctive treatment for subjects with drug-resistant epilepsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study. Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available.
Drug: Padsevonil
* Pharmaceutical Form: film-coated tablet * Route of Administration: Oral use
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Participant and/or Caregiver or Observed by the Investigator During the Entire Study
An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.
Time frame: From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal
An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.
Time frame: From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)
Change From Baseline (From the Respective Parent Study [EP0091 or EP0092]) in Observable Focal-onset Seizure Frequency Over the Evaluation Period
Seizure frequency refers to 28-day adjusted frequency. Observable focal-onset seizures refer to Type IAl, IB, and IC (according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981). Focal-onset seizures include all Type I seizures.
Time frame: From Baseline in respective parent study over the Evaluation Period (up to approximately 2 years) in this study
The study started to enroll study participants in August 2018 and concluded in December 2020.
| Milestone | Padsevonil |
|---|---|
| Started | 406 |
| Completed | 0 |
| Not completed | 406 |
| Withdrew: Adverse event, non-fatal | 24 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Lack of efficacy | 37 |
| Withdrew: Per sponsor's instructions | 1 |
| Withdrew: Study was terminated by parent company ucb | 2 |
| Withdrew: The study was ended by the promoter | 3 |
| Withdrew: Discontinuation of drug development | 3 |
| Withdrew: End of project | 2 |
| Withdrew: Premature study closure | 2 |
| Withdrew: Premature program termination | 1 |
| Withdrew: Premature study termination | 7 |
| Withdrew: Trial terminated by sponsor | 2 |
| Withdrew: Trial discontinued by sponsor | 2 |
| Withdrew: Study ended | 15 |
| Withdrew: Clinical trial has been cancelled | 1 |
| Withdrew: End of study per sponsor decision | 2 |
| Withdrew: Promoter's decision | 2 |
| Withdrew: The trial has been suspended | 3 |
| Withdrew: Sponsor stopped psl development based on data | 3 |
| Withdrew: Early termination by order of sponsor | 2 |
| Withdrew: Discontinuation of the study | 5 |
| Withdrew: End of clinical trial discontinuation | 1 |
| Withdrew: Because the clinical trial ended halfway | 4 |
| Withdrew: Development discontinued | 5 |
| Withdrew: Padsenovil program closed | 3 |
| Withdrew: End of project | 2 |
| Withdrew: Termination of project | 1 |
| Withdrew: The study was interrupted by sponsor | 4 |
| Withdrew: The protocol was interrupted by sponsor | 1 |
| Withdrew: End of sponsor decision | 1 |
| Withdrew: The study was terminated prematurely by study lead | 1 |
| Withdrew: Early termination of studies | 5 |
| Withdrew: This study is ended early | 1 |
| Withdrew: End of padsevonil program | 2 |
| Withdrew: Decision of sponsor | 6 |
| Withdrew: Asked by the sponsor | 3 |
| Withdrew: Sponsor decision to stop the protocol | 1 |
| Withdrew: Pi decision poor compliance from participant | 1 |
| Withdrew: Promoter ended the study | 3 |
| Withdrew: Premature study close by sponsor's decision | 4 |
| Withdrew: Study terminated by sponsor | 33 |
| Withdrew: Sponsor prematurely terminated this study | 2 |
| Withdrew: Sponsor decision to terminate study | 63 |
| Withdrew: Program closure | 3 |
| Withdrew: Study ended prematurely | 1 |
| Withdrew: Study stopped by sponsor | 2 |
| Withdrew: Program termination | 55 |
| Withdrew: Sponsor decision | 62 |
| Withdrew: Sponsor study closure | 10 |
An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.
| percentage of participants | Padsevonil (SS) |
|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Participant and/or Caregiver or Observed by the Investigator During the Entire Study | 72.2 |
An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.
| percentage of participants | Padsevonil (SS) |
|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal | 5.2 |
Seizure frequency refers to 28-day adjusted frequency. Observable focal-onset seizures refer to Type IAl, IB, and IC (according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981). Focal-onset seizures include all Type I seizures.
| seizures per 28 days | Padsevonil (FAS) |
|---|---|
| Change From Baseline (From the Respective Parent Study [EP0091 or EP0092]) in Observable Focal-onset Seizure Frequency Over the Evaluation Period | -7.73 ± 27.52 |
Collected over From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Padsevonil (SS) | 0/406 (0%) | 48/406 (11.8%) | 184/406 (45.3%) |
| Event | Padsevonil (SS) |
|---|---|
| EpilepsyNervous system disorders | 7/406 |
| Generalised tonic-clonic seizureNervous system disorders | 5/406 |
| Status epilepticusNervous system disorders | 5/406 |
| SeizureNervous system disorders | 4/406 |
| Focal dyscognitive seizuresNervous system disorders | 2/406 |
| Partial seizures with secondary generalisationNervous system disorders | 2/406 |
| Seizure clusterNervous system disorders | 2/406 |
| Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders | 2/406 |
| Inappropriate antidiuretic hormone secretionEndocrine disorders | 1/406 |
| Abdominal discomfortGastrointestinal disorders | 1/406 |
| Event | Padsevonil (SS) |
|---|---|
| SomnolenceNervous system disorders | 66/406 |
| HeadacheNervous system disorders | 59/406 |
| FatigueGeneral disorders | 47/406 |
| DizzinessNervous system disorders | 43/406 |
| NasopharyngitisInfections and infestations | 29/406 |
| InsomniaPsychiatric disorders | 23/406 |
| Memory impairmentNervous system disorders | 21/406 |
The Safety Set (SS) consisted of all enrolled participants who were administered at least 1 dose of PSL, based on the first dose date from the first administration of study medication Case Report form (CRF).
| Age, Categorical(Participants) | Padsevonil |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 395 |
| >=65 years | 11 |
| Age, Continuous(years) | Padsevonil |
|---|---|
| Mean | 40.8 ± 12.5 |
| Sex: Female, Male(Participants) | Padsevonil |
|---|---|
| Female | 231 |
| Male | 175 |
| Race/Ethnicity, Customized(Participants) | Padsevonil |
|---|---|
| American Indian / Alaskan native | 5 |
| Asian | 38 |
| Black | 6 |
| Native Hawaiian or other Pacific Islander | 5 |
| White | 343 |
| Other/mixed | 9 |
Showing the first 100 of 156 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Aug 2018 to primary completion in Dec 2020, 27 months.
Results were first posted in Dec 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Padsevonil